ASAhmed Sabra

Ahmed Sabra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Sabra has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Demyelination in Diabetic Distal Symmetric Polyneuropathy: A Retrospective Electrodiagnostic Study

    by Roopa Sharma, Iqra Faiz, Ahmed Sabra, Kazzim Jaffry, Nizaar Souayah, Machteld E. Hillen

    Background: Features of acquired demyelination have been reported in diabetic distal symmetrical polyneuropathy (DDSP). Objectives: To characterize the natural history of demyelination in diabetic distal symmetric polyneuropathy (DDSP). Methods: We retrospectively reviewed serial motor nerve conduction studies in 71 patients with DDSP with ≥2 electrodiagnostic sessions. Patients were categorized as G1 [no new conduction velocity slowing (CVS)], G2 (new CVS), or G3 (new CVS in the demyelinating range per American Academy of Neurology criteria). Age, body mass index, hemoglobin A1c (HbA1c), and study intervals were compared between groups. Results: The cohort included 30 men and 41 women. The mean age and time between the first and most recent studies were 55.91 ± 10.44 years and 32 ± 31 months, respectively. HbA1c was available in 57 patients (mean 7.87 ± 2.61). At the patient level, 30 of 71 (42.2%) had new CVS in ≥1 nerve; among these, 12 of 30 (40.0%) involved a single nerve, 10 of 30 (33.3%) involved 2 nerves, and 8 of 30 (26.7%) involved 3 or more nerves. Demyelinating-range CVS was present in 5 of 30 (16.6%) of those with CVS, corresponding to 5 of 71 (7.0%) of the entire cohort. When stratified by group (Table 2), mean HbA1c differed significantly between G2 and G3 (8.14 ± 2.48 vs. 10.56 ± 5.25; P < 0.05) (Table 4) and between G1 and G3 (7.48 ± 2.21 vs. 10.56 ± 5.25; P < 0.002) (Table 5), while age, body mass index, and interstudy interval showed no significant differences (Tables 3–5). Conclusions: In a subgroup of patients with DDSP, an evolving compound motor action potential independent motor nerve CVS, interval prolongation of the distal motor latency, and interval prolongation or absence of F waves may occur, consistent with a superimposed acquired demyelination. These changes were more frequently identified in patients with higher mean HbA1c values.

  • Open Access

    Medical Complications After Mechanical Thrombectomy: Analysis of Trends in US Admissions From 2010 to 2022

    by Yaxel Levin-Carrion, Ahmed Sabra, Aydan Kahriman, Caryn J. Ha, Momotaz Begum, Ronald Miller, Nemanja Novakovic, Anurag Sahoo, Trong Huynh, Nader El Seblani, et al.

    BACKGROUND: The prevalence of medical complications in patients with acute ischemic stroke undergoing mechanical thrombectomy (MT) is sparse. This study aims to quantify and evaluate trends in common medical complications in acute ischemic stroke MT hospitalizations in the United States over the past decade. METHODS: We utilized the 2010 to 2022 Nationwide Inpatient Sample (NIS) to conduct a serial cross-sectional study. All adult acute ischemic stroke MT hospitalizations (aged ≥18 years) were identified using International Classification of Diseases codes. We computed the weighted prevalence of acute myocardial infarction, acute renal failure, deep venous thrombosis, gastrointestinal bleeding (GIB), pneumonia, pulmonary embolism, sepsis, and urinary tract infection (UTI) across age and sex strata. Poisson regression models were utilized to evaluate the association of each complication with hospital-level factors and to study trends over time. RESULTS: Among 233 812 weighted MT hospitalizations (50.3% women; mean age 68.9 years), 35.9% had at least 1 complication. The age and sex-standardized prevalence was highest for acute renal failure (15.6%), UTI (11.3%), and pneumonia (6.8%), whereas acute myocardial infarction (4.7%), GIB (2%), deep venous thrombosis (4.3%), and pulmonary embolism (1.9%) were less common. Disparities in complication burden were present by age/sex (GIB: women 18–39 years, 0.9%; men ≥80 years, 2.7%). Age/sex-standardized prevalence of acute renal failure increased ≈2-fold across the study period from 11.0% in 2010 to 18.5% in 2022, whereas prevalence of sepsis, pulmonary embolism, and acute myocardial infarction also increased marginally over time (all P -for-trend P -for-trend <0.05); GIB was stable. We report prevalence risk ratios (PRRs); for example, PRR 1.81 indicates an 81% higher prevalence. Each unit increase in National Institutes of Health Stroke Scale score (UTI PRR, 1.02 [95% CI, 1.01–1.02]) and early mechanical ventilation (pneumonia PRR, 3.41 [95% CI, 3.03–3.83]) were associated with increased prevalence of all complications, while intravenous thrombolysis was associated with lower risk for most events (UTI: PRR, 0.91 [95% CI, 0.86–0.96]; sepsis: PRR, 0.77 [95% CI, 0.70–0.84]; pneumonia: PRR, 0.81 [95% CI, 0.75–0.88]). Mortality fell from 23.7% (2010) to 11.8% (2022), whereas routine home discharge rose from 11.9% to 19.9%. All complications were associated with a lower likelihood of routine home discharge, and all except UTI were associated with an increase in in-hospital mortality (sepsis: PRR, 1.55 [95% CI, 1.42–1.67]). CONCLUSIONS: The prevalence of pneumonia and UTI declined, whereas acute renal failure prevalence more than doubled in acute ischemic stroke MT hospitalizations over the last decade. Complications were consistently linked to poorer discharge outcomes and higher in-hospital mortality, underscoring the need for targeted prevention strategies to optimize postthrombectomy care.

  • Real-World Evaluation of Efgartigimod in Generalized Myasthenia Gravis: A Single-Center Experience

    by Roopa Sharma, Ahmed Ba Sabra, Navina Magesh Bs Kumar, Pravallika Mbbs Putrevu, Souayah Md Nizar, Machteld E. Md Hillen

  • Open Access

    Familial Occurrence of Anti‐NF155 Autoimmune Nodopathy in Father and Son: Expanding the Spectrum of IgG4‐Related Nodopathies

    by Roopa Sharma, Ahmed Sabra, Erin Feinstein, Machteld E. Hillen

    We report the first documented familial occurrence of Anti‐Neurofascin‐155 (Anti‐NF155) autoimmune nodopathy in both a father and his son. Anti‐NF155 nodopathy can resemble chronic inflammatory demyelinating polyneuropathy (CIDP) but differs in its poor response to standard CIDP treatments such as intravenous immunoglobulin (IVIG) and steroids, instead requiring B‐cell–depleting therapies. A previously healthy 34‐year‐old male presented with a five‐to‐six week history of subacute sensory ataxia, symmetric proximal and distal weakness, and areflexia, preceded by right‐sided Bell’s palsy. Cerebrospinal fluid (CSF) analysis demonstrated albumin‐cytologic dissociation with a markedly elevated protein level of 485 mg/dL, and nerve conduction studies confirmed a demyelinating polyneuropathy. Despite treatment with IVIG and corticosteroids, he showed minimal improvement, and subsequent detection of Anti‐NF155 antibodies in serum established the diagnosis. He improved significantly with rituximab therapy and was able to walk unassisted at 1‐year follow‐up. Notably, his 13‐year‐old son presented with a similar clinical syndrome at the age of 8, characterized by progressive bilateral weakness, sensory ataxia, tremor, elevated CSF protein of 201 mg/dL, diffuse nerve root enhancement on MRI, and demyelinating polyneuropathy on electrophysiologic studies. He was initially treated as CIDP but failed to respond to IVIG and steroids, later testing positive for Anti‐NF155 antibodies, and has since achieved sustained improvement on rituximab maintenance every six months. This report emphasizes the possibility of genetic predisposition in the pathogenesis of Anti‐NF155 nodopathy and underscores the need for further investigation into familial and environmental factors contributing to disease susceptibility.

  • Trends in the Utilization of Different Carotid Revascularization Modalities in the United States Over a 17-Year Period

    by Fadar O. Otite, Nicholas A. Morris, Ahmed Sabra, Smit D. Patel, Nnabuchi Anikpezie, Anurag Sahoo, David Landzberg, Claribel D. Wee, Amit Singla, Julius Gene Silva Latorre, et al.

    In October 2023, the Centers for Medicare & Medicaid Services (CMS) in the United States expanded coverage for carotid artery stenting (CAS) to include non-high-risk patients with carotid disease. The aim of this study was to provide a 17-year snapshot of trends in carotid revascularization practices in the United States before this CMS policy change went into effect. We conducted a serial cross-sectional study using the 2006-2022 National Inpatient Sample and a retrospective cohort study using the State Emergency and Inpatient Databases of Florida (2005-2021), Georgia (2010-2020), Maryland (2012-2021), and New York (2005-2020). Cases of carotid revascularizations in these databases were identified using International Classification of Diseases codes. We calculated age-specific and sex-specific proportions of revascularizations for CAS and combined annual CAS/carotid endarterectomy (CEA) counts with census data to determine utilization rates per 100,000 population. Joinpoint regression estimated annualized percentage change (APC) over time. Hospitalizations in the 6 months preceding revascularization defined symptomatic vs asymptomatic cases and characterized the subset with symptomatic stenosis. Of 1,779,948 weighted revascularizations, the mean patient age was 71.0 years and 40.9% were performed in women. 17.2% of procedures were CAS, and this proportion more than doubled from 14.3% to 29.0%. Transcarotid artery revascularization accounted for 9.1% in 2022. The CAS proportion increased across age groups, including in those aged older than 70 years and in women, even after excluding mechanical thrombectomy admission. Carotid revascularization usage per 100,000 population declined (APC -3.9%, 95% CI -4.1% to -3.3%) but plateaued after 2015. Although CEA utilization declined from 2006 to 2022 (APC -5.5%, 95% CI -5.9% to -5.1%), CAS use declined from 2006 to 2016 (APC -3.2%, 95% CI -4.6% to -2.1%) but increased from 2016 to 2022 (APC 12.0%, 95% CI 10.1%-14.1%). Only 25.7% of revascularizations in the 4 states were performed for symptomatic disease, with 75.3% of hospitalizations in women for asymptomatic disease. Despite uncertain benefit in selected age and sex groups, including those older than 70 years and with asymptomatic carotid disease, CAS use increased across groups over the past decade and now accounts for >25% of carotid revascularizations in the United States.


  • Open Access

    National trends and complications in the surgical management of diffuse idiopathic skeletal hyperostosis (DISH)

    by Alejandro Pando, Yaxel Levin-Carrion, Caryn J. Ha, Drew Thibault, Marvens Jean, Ahmed Sabra, Daniel Ortega, Kevin Kwan, Hai Sun

    Purpose: Diffuse idiopathic skeletal hyperostosis (DISH) is a noninflammatory disorder characterized by calcification and ossification of ligaments and entheses of the spine. Limited literature exists on the characteristics, complications, and outcomes of patients undergoing different surgical approaches for DISH. This study aims to identify patient factors associated with postoperative complications and predictors of surgical approach. Methods: The 2016 to 2021 National Inpatient Sample (NIS) was used to identify adult inpatients with a primary diagnosis of DISH. From this cohort, those who underwent spine surgery were further identified and subdivided based on the surgical approach and analyzed for demographics, comorbidities, and other patient characteristics to identify associations and trends. Results: Among 5,322 DISH patients, surgical intervention increased from 9.0% in 2016 to 21.5% in 2021. Of 1,560 surgical patients, PDF was more common (68.3%), followed by ADF (18.0%) and APDF (8.7%). ADF had the shortest time to treatment (0.8 ± 2.1 days, p < 0.001), shortest hospital stay (6.0 ± 7.5 days, p < 0.001), and lowest costs ($147,525 ± 137,728, p < 0.001). APDF had the longest hospital stay (9.4 ± 10.6 days, p < 0.001) and highest costs ($361,124 ± 345,692, p < 0.001). Neurologic complications were highest in APDF (14.1% vs. 3.9%, p < 0.001), while ADF had higher dysphagia/aspiration pneumonia rates (35.6% vs. 10.6%, p < 0.001). ADF patients were more likely to be discharged home (55.9% vs. 26.7% PDF, p < 0.001), whereas PDF and APDF patients were more often discharged to skilled nursing/rehabilitation facilities. Independent predictors for PDF included older age (OR: 1.02, p < 0.01) and thoracic spine pathology (OR: 9.31–18.48, p < 0.05). Conclusion: Surgical approach in DISH patients influences outcomes. ADF demonstrates advantages in recovery and costs but increases dysphagia risk. Awareness of surgical risks can improve patient selection and outcomes.